



SAFETY DATA SHEET

Revision date 17-Jun-2025

Version 5

Page 1 / 11

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Cisatracurium Besylate Solution for Injection
Product Code(s) PZ02293
Trade Name: Cisatracurium Besylate
Chemical Family: Not determined

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use Pharmaceutical product

1.3. Details of the supplier of the safety data sheet

Pfizer Inc
66 Hudson Boulevard East
New York, New York 10001
1-800-879-3477

Pfizer Ireland Pharmaceuticals
OSG Building
Ringaskiddy, Co. Cork.
Ireland
+353 21 4378701

E-mail address pfizer-MSDS@pfizer.com

1.4. Emergency telephone number

Emergency Telephone Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Hazardous to the aquatic environment - acute Category 3

OSHA Classification

Hazards not otherwise classified (HNOC)

Not applicable

Hazards classified under paragraph (d)(1)(ii) of 1910.1200

Not applicable

2.2. Label elements

Hazard statements H402 - Harmful to aquatic life

Precautionary Statements - EU (§28, 1272/2008) P273 - Avoid release to the environment
P501 - Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable

SAFETY DATA SHEET

Product Name Cisatracurium Besylate Solution for Injection
Revision date 17-Jun-2025

Page 2 / 11
Version 5

2.3. Other hazards

Other hazards

An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Substances

Not applicable

3.2 Mixtures

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Cisatracurium besylate (CAS #: 96946-42-8)	<1.0		Not Listed	Aquatic Acute 3 (H402)	Not classified	No data available	No data available
Benzenesulfonic acid (CAS #: 98-11-3)	**		202-638-7	Skin Corr 1C (H314) Dam 1 (H318)	Not classified	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water (CAS #: 7732-18-5)	95-100	-	231-791-2	Not classified	Not classified	No data available	No data available

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Benzenesulfonic acid 98-11-3	1100	No data available	No data available	No data available	No data available

SAFETY DATA SHEET

Product Name Cisatracurium Besylate Solution for Injection
Revision date 17-Jun-2025

Page 3 / 11
Version 5

This product does not contain candidate substances of very high concern at a concentration $\geq 0.1\%$ (Regulation (EC) No. 1907/2006 (REACH), Article 59).

Additional information

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
Ingestion	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO₂, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as dust and mists) may fuel fires/explosions.

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

SAFETY DATA SHEET

Product Name Cisatracurium Besylate Solution for Injection
Revision date 17-Jun-2025

Page 4 / 11
Version 5

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.
For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.
Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.
Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling Avoid breathing dust/fume/gas/mist/vapors/spray. Avoid contact with skin, eyes or clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.
General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Cisatracurium besylate
Pfizer OEL TWA-8 Hr: 30 (200 STEL) $\mu\text{g}/\text{m}^3$

SAFETY DATA SHEET

Product Name Cisatracurium Besylate Solution for Injection
Revision date 17-Jun-2025

Page 5 / 11
Version 5

8.2. Exposure controls

Engineering controls	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal protective equipment	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.
Eye/face protection	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
Hand protection	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).
Thermal hazards	No information available.
Environmental exposure controls	No information available.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Appearance	Sterile solution
Physical state	Liquid
Color	Colorless to Pale yellow
Odor	No information available.
Odor threshold	No information available
Property	Values
Melting point / freezing point	No data available
Boiling point or initial boiling point and boiling range	No data available
Flammability (solid, gas)	No data available
Lower and upper explosion limit/flammability limit	
Lower explosion limit	No data available
Upper explosion limit	No data available
Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	
SADT (°C)	No data available
pH	No data available
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available

SAFETY DATA SHEET

Product Name Cisatracurium Besylate Solution for Injection
Revision date 17-Jun-2025

Page 6 / 11
Version 5

Dynamic viscosity	No data available
Solubility	No data available
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

9.2. Other information

Molecular formula	Mixture
Molecular weight	Mixture

9.2.1. Information with regard to physical hazard classes

No information available

9.2.2. Other safety characteristics

No information available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

Stability Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

General Information: The information included in this section describes the potential hazards of the individual ingredients

Short term Accidental ingestion may cause effects similar to those seen in clinical use.
Known Clinical Effects: Adverse effects associated with therapeutic use include decreased heart rate (bradycardia), decrease in blood pressure (hypotension), flushing, difficulty breathing, skin rash, and neuromuscular block. Hypersensitivity reactions may also occur in susceptible individuals.

Acute toxicity Based on available data, the classification criteria are not met.

Serious eye damage/eye irritation Based on available data, the classification criteria are not met.

SAFETY DATA SHEET

Product Name Cisatracurium Besylate Solution for Injection
Revision date 17-Jun-2025

Page 7 / 11
Version 5

Skin corrosion/irritation Based on available data, the classification criteria are not met.
Respiratory or skin sensitization Based on available data, the classification criteria are not met.
STOT - single exposure Based on available data, the classification criteria are not met.
STOT - repeated exposure Based on available data, the classification criteria are not met.
Reproductive toxicity Based on available data, the classification criteria are not met.
Germ cell mutagenicity Based on available data, the classification criteria are not met.
Carcinogenicity Based on available data, the classification criteria are not met.
Aspiration hazard Based on available data, the classification criteria are not met.

Acute Toxicity: (Species, Route, End Point, Dose)

Benzenesulfonic acid

Rat Oral LD50 > 1104 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
Benzenesulfonic acid	= 1100 mg/kg (Rat)	-	-

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Benzenesulfonic acid

Skin irritation Rabbit Corrosive
Eye irritation Rabbit Corrosive

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Cisatracurium besylate

3 Week(s) Monkey Intravenous * 3.75 mg/kg/day NOAEL None identified
3 Week(s) Dog Intravenous * 2 mg/kg/day NOAEL None identified

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Cisatracurium besylate

Embryo / Fetal Development Rat Intravenous 4 mg/kg/day NOAEL Not teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Cisatracurium besylate

Bacterial Mutagenicity (Ames) *Salmonella* Negative
In Vitro Cytogenetics Human Lymphocytes Negative
In Vitro Cytogenetics Rat Bone marrow Negative
In Vitro Mammalian Cell Mutagenicity Mouse Lymphoma Positive

Carcinogenicity None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

11.2.2. Other information

Other adverse effects No information available.

Section 12: ECOLOGICAL INFORMATION

SAFETY DATA SHEET

Product Name Cisatracurium Besylate Solution for Injection
Revision date 17-Jun-2025

Page 8 / 11
Version 5

Environmental Overview: Environmental properties have not been thoroughly investigated. The following information is available for the individual ingredients.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Cisatracurium besylate

Daphnia magna (Water Flea) OECD EC50 48 hours 14 mg/L

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Cisatracurium besylate

Activated sludge OECD IC50 > 4000 mg/L

12.2. Persistence and degradability

Persistence and degradability No information available.

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

Cisatracurium besylate

OECD Ready 82.26 % After 28 Day(s) Ready

Photolysis: (Method, pH, Endpoint, Results)

Cisatracurium besylate

OECD 5 Half-Life 2.45 Day(s)

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment

Chemical name	PBT and vPvB assessment
Benzenesulfonic acid	Not PBT/vPvB PBT assessment does not apply

12.6. Endocrine disrupting properties

Endocrine disrupting properties Based on available data, the classification criteria are not met.

12.7. Other adverse effects

Other adverse effects

No information available.

PMT or vPvM properties

Based on available data, the classification criteria are not met.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review

SAFETY DATA SHEET

Product Name Cisatracurium Besylate Solution for Injection
Revision date 17-Jun-2025

Page 9 / 11
Version 5

and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:	Not applicable
UN proper shipping name:	Not applicable
Transport hazard class(es):	Not applicable
Packing group:	Not applicable
Environmental Hazard(s):	Not applicable

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present

Cisatracurium besylate

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 4

Benzenesulfonic acid

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	202-638-7
AICS	Present

National regulations

Germany

Chemical Prohibition Ordinance (ChemVerbotsV)
Not applicable

TRGS 905 Not applicable

SAFETY DATA SHEET

Product Name Cisatracurium Besylate Solution for Injection
Revision date 17-Jun-2025

Page 10 / 11
Version 5

Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018 Not applicable
Storage of Hazardous Material Not applicable
WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20 Not applicable
Major Accidents Ordinance SR 814.012 Not applicable

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

Explosives Precursors Marketing and Use (2019/1148)

Not applicable

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory
DSL/NDL - Canadian Domestic Substances List/Non-Domestic Substances List
EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances
ENCS - Japan Existing and New Chemical Substances
IECSC - China Inventory of Existing Chemical Substances
KECL - Korean Existing Chemicals Inventory
PICCS - Philippines Inventory of Chemicals and Chemical Substances
AICS - Australian Inventory of Chemical Substances
NZIoC - New Zealand Inventory of Chemicals
TCSI - Taiwan Chemical Substance Inventory

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H402 - Harmful to aquatic life; H314 - Causes severe skin burns and eye damage H318 - Causes serious eye damage

Data Sources:

Safety data sheets for individual ingredients. Publicly available toxicity information. Pfizer proprietary drug development information.

SAFETY DATA SHEET

Product Name Cisatracurium Besylate Solution for Injection
Revision date 17-Jun-2025

Page 11 / 11
Version 5

Reason for revision Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal Protection.

Revision date 17-Jun-2025

Prepared By Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.